Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

Most women continued using oral minoxidil for hair loss despite mild to moderate side effects.

This study reported that 57% of healthcare workers experienced persistent post-COVID-19 complications, with common symptoms including hair loss, easy fatigability, mood swings, and anxiety.

Low-dose oral minoxidil can cause dizziness in women without lowering blood pressure, so careful monitoring is needed.

In this retrospective study, researchers found that while combination therapy of spironolactone and oral minoxidil for female alopecia commonly led to mild outpatient-manageable side effects, starting both medications simultaneously reduced hypertrichosis risk, but taking multiple blood pressure medications increased hypotensive symptoms.

Low-glycemic index diets are beneficial for weight loss and satiety, but more research is needed on long-term effects and individualized approaches are recommended.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This study observed a slight reduction in blood pressure in normotensive patients after taking a 5-mg dose of oral minoxidil, particularly within the first two hours and more so in those with high baseline blood pressure.

This case report describes two women experiencing hormonally associated vestibulodynia and female arousal disorder, potentially linked to the use of spironolactone for androgen-mediated cutaneous disorders.

This study found no baseline factors that predicted flibanserin efficacy for HSDD, though low testosterone or use of hormonal contraceptives were associated with reduced efficacy.

A bald man grew hair on his head after taking a drug called diazoxide, but lost it again when he stopped the medication.

This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.

This review discusses the nutritional and metabolic problems following bariatric surgery, emphasizing the need for ongoing monitoring and treatment, but reports no new clinical results.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

This study found that fluoxetine did not demonstrate short-term efficacy in treating trichotillomania in a placebo-controlled, double-blind crossover setting.

This systematic review concluded that the support for using spironolactone at commonly prescribed doses is based on evidence of limited quality.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This review discusses the hormonal influences on acne's development in women and the therapeutic potential of hormonal treatments, but it reports no new clinical results.

This study found significant weight loss and reductions in blood pressure and serum triglycerides among obese patients following a multidisciplinary program with a very low calorie ketogenic diet.

Many COVID-19 survivors experience long-term symptoms like fatigue and sleep issues, needing ongoing medical support.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalp cooling is the most effective prevention method in most cases, though some questions remain.

In this study, jaw wiring led to significant weight loss in patients with severe obesity, but two-thirds regained weight after the wires were removed.

This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.

This review examines complementary and alternative medicine for alopecia and finds limited support from robust clinical trials, highlighting the need for standardized studies to evaluate efficacy and safety.

This article reviews different acne treatments and emphasizes the importance of being aware of their potential side effects, but reports no new clinical results.